Skip to main content
SpringerLink
Log in
Book cover

Small Molecules in Oncology pp 177–186Cite as

Cobimetinib (GDC-0973, XL518)

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 211))

Abstract

The mitogen-activated protein kinase cascade (MAPK/ERK pathway) is a signaling pathway activated as a cellular response to various stimuli and for regulating the proliferation and survival of several types of eukaryotic cells, among others a wide variety of tumor cells. Mutations of the proteins involved in this pathway have been discovered in several tumor entities, indicating their inhibition as a potential therapeutic target. BRAF inhibitors have been in the clinical use since 2011. Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past. After trametinib, cobimetinib is another potent, selective oral MEK1/2 inhibitor that was approved by European Medicine Agency (EMA) and Food and Drug Administration (FDA) in 2015 for treatment of malignant melanoma in a combination with the BRAF inhibitor vemurafenib.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J (2016) Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X

    Article  PubMed  CAS  Google Scholar 

  • Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, Cobb MH (1990) An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249:64–67

    Article  CAS  PubMed  Google Scholar 

  • Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY (2016) Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet 55:1435–1445. https://doi.org/10.1007/s40262-016-0412-5

    Article  PubMed  CAS  Google Scholar 

  • Cobb MH, Boulton TG, Robbins DJ (1991) Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 2:965–978

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954. https://doi.org/10.1038/nature00766

    Article  PubMed  CAS  Google Scholar 

  • Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob J-J, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA (2017) Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 28:1137–1144. https://doi.org/10.1093/annonc/mdx040

    Article  PubMed  Google Scholar 

  • Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950. https://doi.org/10.1093/nar/gkq929

    Article  PubMed  CAS  Google Scholar 

  • Han K, Jin JY, Marchand M, Eppler S, Choong N, Hack SP, Tikoo N, Bruno R, Dresser M, Musib L, Budha NR (2015) Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol 76:917–924. https://doi.org/10.1007/s00280-015-2862-0

    Article  PubMed  CAS  Google Scholar 

  • Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JFM, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh S-M, Anderson DJ, Ludlam MJC, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501:232–236. https://doi.org/10.1038/nature12441

    Article  PubMed  CAS  Google Scholar 

  • Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin A-M, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365. https://doi.org/10.1016/S0140-6736(12)60868-X

    Article  PubMed  CAS  Google Scholar 

  • Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang N-Y, Engst S, Johnston S, Friedman LS, Belvin M (2012) Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72:210–219. https://doi.org/10.1158/0008-5472.CAN-11-1515

    Article  PubMed  CAS  Google Scholar 

  • Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, Hoeflich KP, Singh M (2015) Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Mol Cancer Ther 14:40–47. https://doi.org/10.1158/1535-7163.MCT-14-0030

    Article  PubMed  CAS  Google Scholar 

  • Kirkpatrick DS, Bustos DJ, Dogan T, Chan J, Phu L, Young A, Friedman LS, Belvin M, Song Q, Bakalarski CE, Hoeflich KP (2013) Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proc Natl Acad Sci 110:19426–19431. https://doi.org/10.1073/pnas.1309473110

    Article  PubMed  CAS  Google Scholar 

  • Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876. https://doi.org/10.1056/NEJMoa1408868

    Article  PubMed  CAS  Google Scholar 

  • Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J (2017) A phase Ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced or metastatic cancers with mutant KRAS. Oncologist 22:1024–e89. https://doi.org/10.1634/theoncologist.2017-0175

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob J-J, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451. https://doi.org/10.1016/S0140-6736(15)60898-4

    Article  CAS  Google Scholar 

  • McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O’Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A (2014) Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332. https://doi.org/10.1016/S1470-2045(14)70012-9

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Moodie SA, Willumsen BM, Weber MJ, Wolfman A (1993) Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260:1658–1661

    Article  CAS  PubMed  Google Scholar 

  • Musib L, Choo E, Deng Y, Eppler S, Rooney I, Chan IT, Dresser MJ (2013) Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm 10:4046–4054. https://doi.org/10.1021/mp400383x

    Article  PubMed  CAS  Google Scholar 

  • Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol 15:954–965. https://doi.org/10.1016/S1470-2045(14)70301-8

    Article  PubMed  CAS  Google Scholar 

  • Robbins DJ, Cheng M, Zhen E, Vanderbilt CA, Feig LA, Cobb MH (1992) Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc Natl Acad Sci USA 89:6924–6928

    Article  CAS  PubMed  Google Scholar 

  • Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin A-M, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690

    Article  PubMed  CAS  Google Scholar 

  • Roskoski R (2017) Allosteric MEK1/2 inhibitors including cobimetinib and trametinib in the treatment of cutaneous melanomas. Pharmacol Res 117:20–31. https://doi.org/10.1016/j.phrs.2016.12.009

    Article  PubMed  CAS  Google Scholar 

  • Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CECA, Khojasteh SC, Dresser MJ, Musib L (2015) Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]Cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos 44:28–39. https://doi.org/10.1124/dmd.115.066282

    Article  PubMed  CAS  Google Scholar 

  • Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini J-F, Yu P, Li C, Rosario GD, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J (2012) Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res 18:3090–3099. https://doi.org/10.1158/1078-0432.CCR-12-0445

    Article  PubMed  CAS  Google Scholar 

  • Yan Y, McArthur G, Hamid O, Puzanov I, Gonzalez R, Gajewski T, Wang Y, Wongchenko M, Choong N, Ribas A (2014) Biomarker analysis of on-treatment and at progression biopsies from BRIM7—a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma. J Transl Med 12:O12. https://doi.org/10.1186/1479-5876-12-S1-O12

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany

    Hana Andrlová & Robert Zeiser

  2. Department of Dermatology and Venereology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstr. 7, 79104, Freiburg, Germany

    Frank Meiss

Authors
  1. Hana Andrlová
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Zeiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Meiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hana Andrlová .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Andrlová, H., Zeiser, R., Meiss, F. (2018). Cobimetinib (GDC-0973, XL518). In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 211. Springer, Cham. https://doi.org/10.1007/978-3-319-91442-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91442-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91441-1

  • Online ISBN: 978-3-319-91442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation